TAILIEUCHUNG - Guideline for Alzheimer’s Disease Management

Questions to ask are how serious would it be if a particular record 5 or 10 years from now were unavailable? What are the chances of it being needed? Are the consequences serious enough to justify keeping a large volume of records for long periods of time at considerable cost? Is the information available anywhere else? What would it cost to reconstruct the record if necessary? Answering these questions will lead to a more realistic approach to the problem of determining how long records should be kept | Guideline for Alzheimer s Disease Management California Workgroup on Guidelines for Alzheimer s Disease Management FINAL REPORT 2008 Supported by the State of California Department of Public Health CALIFORNIA VERSION April 2008 Guideline for Alzheimer s Disease Management California Workgroup on Guidelines for Alzheimer s Disease Management FINAL REPORT 2008 Supported by the State of California Department of Public Health CALIFORNIA VERSION April 2008 Acknowledgments We gratefully acknowledge the members of the California Workgroup on Guidelines for Alzheimer s Disease Management for their efforts in updating this guideline. This effort would not have been possible without their participation in the following work groups Executive Committee Debra Cherry PhD Co-Director Alzheimer s Association Calif. Southland Freddi Segal-Gidan pa PhD Co-Director USC ADRC USC Rancho Los Amigos ARCC Patrick Fox MSW PhD UCSF Institute for Health Aging Carol Hahn MSN RN Manager Alzheimer s Association Calif. Southland James Howard ms California Department of Public Health KATHoNy Jerauld MPH California Department of Public Health Neal Kohatsu MD MPH California Department of Public Health Kit Lackey California Department of Public Health Brian Mittman PhD VA Greater LA Healthcare System at West LA Dodie Tyrrell ma California Department of Public Health Barbara Vickrey MD MPH UCLA Alzheimer s Center Assessment Josh Chodosh MD Co-Chair VA Greater LA Healthcare System UCLA Division of Geriatrics Laura Mosqueda MD Co-Chair Program in Geriatrics UCI School of Medicine Linda Aoyama MD Healthcare Partners Medical Group Michael-Anne Browne MD Blue Shield of California Tony Kuo MD MSHS Office of Senior Health LA County Dept. of Public Health Verna Porter MD UCLA Department of Neurology Lisa Yarick MSW Kaiser Permanente Reporting Requirements Fay Blix JD Chair National Academy of Elder Law Attorneys Kit Lackey California Department of Public Health Janet Morris JD Bet Tzedek Legal Services .

• Y khoa - Dược
• carefully monitored
• branded generic
• disease programmes
• Neuropsychiatric Manifestations
• AIDS and Trauma
• Cutaneous Manifestation
• Plant Interaction
• Plant Soil
• Microorganism Interactions